CYTOMX THERAPEUTICS INC
NASDAQ: CTMX (CytomX Therapeutics, Inc.)
最近更新时间: 7小时之前0.802
0.04 (5.90%)
| 前收盘价格 | 0.757 |
| 收盘价格 | 0.770 |
| 成交量 | 1,400,267 |
| 平均成交量 (3个月) | 1,927,695 |
| 市值 | 64,240,120 |
| 市盈率 (P/E TTM) | 2.11 |
| 预期市盈率 (P/E Forward) | 1.07 |
| 价格/销量 (P/S) | 0.490 |
| 股市价格/股市净资产 (P/B) | 5.04 |
| 52周波幅 | |
| 利润日期 | 6 May 2025 - 12 May 2025 |
| 营业毛利率 | 23.08% |
| 营业利益率 (TTM) | 46.41% |
| 稀释每股收益 (EPS TTM) | 0.380 |
| 季度收入增长率 (YOY) | 43.20% |
| 季度盈利增长率 (YOY) | 2,155.20% |
| 流动比率 (MRQ) | 1.25 |
| 营业现金流 (OCF TTM) | -86.23 M |
| 杠杆自由现金流 (LFCF TTM) | -44.20 M |
| 资产报酬率 (ROA TTM) | 9.69% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | CytomX Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.13 |
|
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.15% |
| 机构持股比例 | 57.87% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Laurion Capital Management Lp | 31 Dec 2024 | 1,248,364 |
| 52周波幅 | ||
| 中 | 2.50 (211.72%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 14 Apr 2025 | 2.50 (211.72%) | 购买 | 0.606 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合